For personal use only

**ASX Release**

4 November 2026

## CHAIR'S ADDRESS AND CEO PRESENTATION TO ANNUAL GENERAL MEETING

**MELBOURNE, AUSTRALIA 4 November 2026:** Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, provides the Chair's address and the CEO's presentation for today's Annual General Meeting.

The meeting commences at 11:00am AEDT held virtually via an online platform. Full details of the meeting can be found in the Notice of Annual General Meeting dated 5 October 2026, available at https://www.arovella.com/asx-announcements.

*Release authorised by the Arovella Therapeutics Ltd Board of Directors.*

**FURTHER INFORMATION**

**Dr Nicole van der weerden**
Chief Executive Officer
**E** nvanderweerden@arovella.com
**M** +61 407 039 983

**David Williams**
Chairman
**E** dwilliams@kidder.com.au
**M** + 61 414 383 594

**About the SAPPHIRE trial**

The initial dose escalation part of the trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of a single dose of ALA-101. During dose escalation, dosing will be staggered in accordance with regulatory requirements as part of IND approval to ensure adequate safety review between patients. Initial data from the trial are expected to be available early in CY2027.

The study incorporates a backfill Bayesian Optimal Interval (BF-BOIN) design to enable adaptive dose escalation and efficient allocation of participants to dose levels with an acceptable emerging safety profile as they become available. Backfill enrolment will commence only once a dose level has been reviewed and confirmed acceptable from a safety perspective. The dose expansion/backfill part of the trial will further characterise the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ALA-101. Generating additional data at dose levels with acceptable safety profiles is intended to provide a robust basis for selecting the most appropriate dose to advance into a phase 2 study, informed by the overall balance of safety and preliminary activity. It also provides flexibility to expand enrolment in specific disease subtypes based on emerging data, allowing promising signals of clinical activity to be explored in greater depth within the trial.

**About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

**Glossary: iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1d, which is expressed on some immune cells and cancer cells.

For more information, visit www.arovella.com

For personal use only

ASX:**ALA**



For personal use only

arovella
THERAPEUTICS

# Annual General Meeting

Wednesday, 4 November 2026



For personal use only

# Introduction

Mr David Williams

# Arovella's Board of Directors

For personal use only



## Mr David Williams

**CHAIRMAN**

David is one of Australia's best known investment bankers in pharmaceuticals, medical devices, and in food and agriculture. He has advised many of Australia's leading companies and played a key role in high profile transactions and advice such as the sale of SPC, the introduction of the Green Whistle pain relief device PolyNovo wound care device.



## Dr Nicole Van Der Weerden

**CHIEF EXECUTIVE OFFICER**

Dr van der Weerden is an experienced biopharmaceutical executive with more than 15 years of experience in the sector. Dr van der Weerden has a track record of driving business objectives in pre-clinical discovery, proof-of-concept, manufacturing, and clinical development.



## Dr Michael Thurn

**NON-EXECTUIVE DIRECTOR**

Dr Michael Thurn has over 25 years' experience in drug development and executive leadership across the biotechnology sector. He has held senior roles at Neurizon Therapeutics, Botanix Pharmaceuticals, Mimetica and Spinifex Pharmaceuticals, and brings deep expertise in regulatory strategy, including drug evaluation with the Therapeutic Goods Administration.



## Mr Mark Diamond

**NON-EXECTUIVE DIRECTOR**

Mr Diamond is a senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than thirty years within the pharmaceutical and biotechnology industries. He was previously MD and CEO at Antisense, and has also served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations. Mark is currently a Senior Advisor for Boston based Global Investment Bank, Locust Walk, Biotech Advisor for Spark Plus, a Corporate Advisory specialist firm in Singapore and Chair of Dimerix Limited (ASX:DXB).

# Agenda

## Annual General Meeting, 4 November 2026

For personal use only

- Formal Business
- Chair Address: David Williams
- CEO Address: Nicole van der Weerden
- Interview with Jacqueline Cumming: Clinical Development
- Interview with Michelle Ferguson: Research & Development



# Formal Business

## RESOLUTIONS

**RESOLUTION 1:** Adoption of Remuneration Report

**RESOLUTION 2:** Election of David Williams as a Director

**RESOLUTION 3:** Election of Mark Diamond as a Director

**RESOLUTION 4:** Election of Michael Thurn as a Director

**RESOLUTION 5:** Approval for Issue of Performance Rights to David Williams under LTIP

**RESOLUTION 6:** Amendment to Constitution of the Company

**RESOLUTION 7:** Renewal of Proportional Takeover Provisions in the Company's Constitution

**RESOLUTION 8:** Renewal of Shareholder Approval for LTIP

**RESOLUTION 9:** Ratification of Prior Issue of Options to Blue Ocean Equities

**RESOLUTION 10:** Approval of Additional 10% Placement Capacity

For personal use only

# 2026 Annual Report

To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditors' Reports in respect of the financial year ended 30 June 2026.

For personal use only

# **RESOLUTION 1:** Adoption of Remuneration Report

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as a **non-binding ordinary** resolution:

*'That the Remuneration Report of the Company and its controlled entities for the year ended 30 June 2026 be adopted.'*

# **RESOLUTION 2:** Election of David Williams as a Director

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary** resolution:

> *'That David Williams, who was appointed a Director on 28 April 2026, retires in accordance with ASX Listing Rule 14.4 and rule 47(d) of the Constitution and being eligible, be elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 2 in the notice of meeting.'*

# **RESOLUTION 3:** Election of Mark Diamond as a Director

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary** resolution:

> '*That Mark Diamond, who was appointed a Director on 28 April 2026, retires in accordance with ASX Listing Rule 14.4 and rule 47(d) of the Constitution and being eligible, be elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 3 in the notice of meeting.*'

# **RESOLUTION 4:** Election of Michael Thurn as a Director

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary** resolution:

> *'That Michael Thurn, who was appointed a Director on 28 April 2026, retires in accordance with ASX Listing Rule 14.4 and rule 47(d) of the Constitution and being eligible, be elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 4 in the notice of meeting.'*

# **RESOLUTION 5:** Approval for Issue of Performance Rights to David Williams under the LTIP

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary** resolution**:**

> *'That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of 8,000,000 Performance Rights to David Williams under the LTIP, on the terms and conditions set out in the Explanatory Memorandum accompanying and forming part of the Notice of this Meeting.*

# **RESOLUTION 6:** Amendment to Constitution

To consider and, if thought fit, pass the following resolution as a **special** resolution:

*'That the constitution of the Company is amended as follows:*

*(a) insert immediately after 'calculated' where appearing in clause 50(c) 'unless the non-cash benefit is covered by clause 50(ca)'; and*

*(b) insert immediately after clause 50(c) the following new clause 50(ca):*
*'(ca) Non-cash benefits comprising shares, options, rights, other securities and share-based payments may be provided to Non-Executive Directors as part of their fees under clause 50 according to the rules of any share, option, right or other security plan for the remuneration of Non-Executive Directors that may be or has previously been introduced by the Company, subject to the Listing Rules and requirements of the Corporations Act. The value of any such non-cash benefits will not be included in the amount determined by the Company in general meeting for the purposes of clause 50(a),*

*and that any increase in the total aggregate amount of directors' fees payable to non-executive directors consequent on the grant of Options or Performance Rights under the LTIP is approved for the purposes of Listing Rule 10.17 and for all other purposes.'*

For personal use only

# **RESOLUTION 7:** Renewal of Proportional Takeover Provisions in the Company's Constitution

For personal use only

To consider and, if thought fit, pass the following resolution as a **special** resolution:

> *'That, in accordance with section 648G(4) of the Corporations Act 2001 (Cth), approval is given for the renewal of clause 79 and 80 of the Company's constitution by maintaining that clause in the Company's constitution for the period of 3 years from the date of this Meeting.'*

# **RESOLUTION 8:** Renewal of Shareholder Approval for the LTIP

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary** resolution:

*'That, for the purposes of Listing Rule 7.2 Exception 13 and for all other purposes, the Arovella Long Term Incentive Plan Rules (LTIP), the terms of which are summarised in the Explanatory Notes, be Approved'*

# **RESOLUTION 9:** Ratification of Prior Issue of Options

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary** resolution:

> *'That, for the purpose of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 2,000,000 Options to Blue Ocean Equities (or their nominee) by the Company on the terms and conditions as more fully described in the Explanatory Memorandum accompanying the Notice of this Meeting.'*

# **RESOLUTION 10:** Approval of Additional 10% Placement Capacity

For personal use only

To consider and, if thought fit, pass with or without amendment the following resolution as a **special** resolution:

> *'That, for the purpose of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to an additional 10% of its issued Equity Securities by way of placements over a 12-month period, on the terms and conditions as more fully described in the Explanatory Memorandum accompanying the Notice of this Meeting.'*

ASX:**ALA**

arovella THERAPEUTICS

For personal use only

# Poll





For personal use only

# CEO Address

Dr Nicole Van Der Weerden

# Disclaimer

For personal use only

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

3. Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The presentation includes forward-looking statements regarding future events and the future financial performance of Arovella. Forward looking words such as “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” or other similar expressions are intended to identify forward-looking statements. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Arovella and its officers, employees, agents or associates. In particular, factors such as outcomes of clinical trials and regulatory decisions and processes may affect the future operating and financial performance of Arovella. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The information also assumes the success of Arovella’s business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. Arovella is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

4. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

5. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

6. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.


7. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

# Key achievements for FY26

## Transformation to a clinical-stage company

For personal use only

### Structurally differentiated next-generation cell therapy




### ALA-101 into clinic

- FDA IND accepted
- GMP drug product manufactured and released
- **First patient dosed in phase 1 study**

### ALA-105 into development

- **Potent proof-of-concept data for CLDN18.2 CAR-iNKT cells**
- Demonstrated benefit of Arovella's IL-12-TM armouring technology

### Pipeline expansion

- **Expanding ALA-101 into autoimmune disease**
- Evaluating new technologies to enhance persistence of our cells
- Assessing new solid tumour targets

Arovella is building a platform to support multiple future therapies.

# Cell Therapy has revolutionised blood cancer treatment

## CAR-T therapies have demonstrated curative potential in blood cancers


For personal use only



The CAR-T market is expected to reach

**$15.2 billion**

by 2035[1]




### Cure

CAR-T cells have demonstrated ability to **cure haematological cancers**



### Strong Sales



### 40-60%

Patients relapse post-CAR-T therapy[2]

| Product | Approval Year | 2025 Revenue |
|---|---|---|
| CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV Infusion | 2022 | US$1.9 bil[3] |
| YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion | 2017 | US$1.5 bil[4] |
| Breyanzi® (lisocabtagene maraleucel) SUSPENSION FOR IV INFUSION | 2021 | US$1.36 bil[5] |









*Footnotes: See appendix at the end of this presentation.*


# CAR-T technology challenges

**Only** treats the patient who supplied the T cells





Each manufacturing batch is **patient-specific**

Patient must wait **3-4 weeks** for therapy



- Manufacturing & supply chain **costs high, failures can occur**
- T cells **can be compromised** by disease
- **Limited centres** can collect and manufacture
- **Time is an issue** for patients with aggressive disease

# ALA's off-the-shelf solution:




One CAR-iNKT batch **treats multiple patients**

**1 week**


Patients ready to dose within 1 week

For personal use only

# CAR-iNKT cells – a differentiated immune cell

## Potential to overcome core limitations of CAR-T

For personal use only




## Multiple ways to attack tumours

1 **ALLOGENEIC WITHOUT GENE EDITING**

**Off-the-shelf solution; no gene editing required** (preserves cell fitness)

2 **MULTIPLE WAYS TO KILL CANCER CELLS**

**Reduces the likelihood of antigen escape; potential for better efficacy**

3 **INFILTRATE TUMOURS**

**Potential for better efficacy than CAR-T for solid tumours**

4 **MODULATE THE TME AND IMMUNE SYSTEM**

**Shape the tumour microenvironment to block and kill pro tumour cells; secrete signalling molecules to activate other immune cells**




***Abbreviations***: *TAM, Tumour Associated Macrophage; MDSC, Myeloid Derived Suppressor Cell; CAR, Chimeric Antigen Receptor; NK, Natural Killer; NKG2D, Natural Killer Group 2, member D*

# World-class CAR-iNKT manufacturing platform with FDA IND

## Semi-automated process suitable for large-scale and late-phase clinical development


For personal use only

### Arovella Manufacturing Platform











Collect Healthy Donor Blood


Isolate iNKT cells






Engineer iNKT cells to produce CARs

Expand to grow billions of CAR-iNKT cells





Vial and freeze CAR-iNKT cells



Lentivirus for any CAR

Arovella believes it has one of the most advanced donor-derived CAR-iNKT development programs*, with an FDA-accepted IND

cell therapies



*Based on publicly disclosed information; **Abbreviations**: CAR, Chimeric Antigen Receptor; FDA, U.S Food and Drug Administration; IND, Investigational New Drug

For personal use only



# ALA-101 (CAR19-iNKT cells)

A next generation **off-the-shelf** cell therapy for CD19 expressing cancers

# ALA-101: an off-the-shelf solution for CD19+ blood cancers

First-in-human study commenced

For personal use only

## FDA IND accepted for CD19+ lymphomas and leukaemias




### Validated target with potential for indication expansion

Possibility to expand into autoimmunity if phase 1 trial supports B cell depletion

### Addresses key CAR-T challenges

- **Safety -** Low risk of GvHD; properties of iNKT cells may decrease toxicity
- **Scalability and cost -** Allogeneic, off-the-shelf manufacturing produces multiple doses/batch
- **Patient access** – Potential for improved safety may allow for outpatient administration
- **Healthier starting material** – Avoids T cell dysfunction and exhaustion seen in heavily pre-treated patients





***Abbreviations***: *GvHD, graft versus host disease*

# ALA-101-001 Phase 1 study; Blood Cancer

**Study population** ▶ Adults with relapsed/refractory CD19-positive B cell cancers ▶ **NHL (DLBCL • FL • MZL • MCL)** **Leukaemia (CLL • HCL)**

## Patient journey

**1. Screening**
Confirm eligibility, disease status + baseline samples

▶

**2. Lymphodepletion**
Conditioning chemotherapy prepares immune space

▶

**3. ALA-101 infusion**
Single dose of healthy donor CD19 CAR-iNKT cells

▶

**4. On-study follow-up**
Safety, response + biology through Month 24

▶

**5. Long-term follow-up**
Continued monitoring after end-of-study visit

## Study design: dose escalation with backfill / expansion

**Dose escalation**
Up to 4 dose levels; ~13–21 participants

**Backfill / expansion**
Further efficacy + biology
Up to 25 additional participants

**≤46 total**
Planned participants

**DLT review** Safety + tolerability

*Backfill can occur in multiple dose levels to better assess dose-response*

***Goal: Identify a recommended Phase 2 dose based on safety, pharmacology, expansion, persistence and preliminary efficacy***

## Outcome measures

**If successful, ALA-101 could demonstrate:**

- ✓ CAR-iNKT cells are safe in humans
- ✓ Donor-derived CAR-iNKT cells can expand and persist
- ✓ CD19-expressing blood cancers can be controlled
- ✓ ALA-101 can deplete B cells

## Study results inform development of Arovella's future products

**CD19 blood cancers**
Defines dose, safety profile and first efficacy signals for next-stage of development.

**Solid tumours**
Informs persistence, trafficking, immune activation and resistance biology for future CAR-iNKT targets.

**Autoimmunity**
Builds data on B cell depletion, durability and donor compatibility for future autoimmune indications.

***Abbreviations:*** *NHL = non-Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma; MCL, mantle cell lymphoma; CLL = chronic lymphocytic leukemia; HCL = hairy cell leukemia; DLT = dose-limiting toxicity;*

For personal use only

# The autoimmune opportunity for ALA-101

## CD19 cell therapy is emerging as a new approach to treat autoimmune disease

For personal use only

### The problem


Serious autoimmune diseases such as lupus, myositis, stiff person syndrome, generalized myasthenia gravis, and systemic sclerosis, are driven by abnormal B cells and are typically managed with lifelong immune suppression rather than cured.

### The breakthrough

Several clinical studies have demonstrated the ability of CD19-targeting CAR-T therapies that target B cells to produce meaningful clinical responses in patients with a range of severe and refractory autoimmune disorders and allow the discontinuation of immunosuppressive therapy.

### Why it matters for Arovella

ALA-101 targets CD19. Arovella's SAPPHIRE phase 1 trial is designed to generate the B cell depletion, safety, persistence and durability data that may support the evaluation of ALA-101 in autoimmune disease.




ALA-101 clinical trial in blood cancers

↓

Proves safety, dosing, persistence & B cell depletion

↓

Potential CD19 autoimmune expansion using the same product, target and manufacturing process



For personal use only

# ALA-105 (CLDN18.2 CAR-iNKT)


A clinically validated target that is expressed in several solid tumour types

# An off-the-shelf solution for solid tumours

## With ALA's proprietary cytokine armouring

For personal use only

### Novel, proprietary CLDN18.2-targeting CAR




### Validated target with high unmet need

Potential to target a broad range of cancers

### Addresses key CAR-T challenges

- **Efficacy** – iNKT cells:
  - naturally infiltrate tumours better than T cells[6]
  - kill pro-tumour cells and activate helpful immune cells[7]
  - also target NKG2D ligands on tumour cells[8]
- **Safety** – Low risk of GvHD; properties of iNKT cells may decrease toxicity
- **Scalability and cost -** Allogeneic, off-the-shelf manufacturing produces multiple doses/batch




***Abbreviations***: *IND, Investigational New Drug Application.*
*Footnotes: See appendix at the end of this presentation.*

# CLDN18.2-targeting CAR-iNKT cells are highly potent

## Complete tumour clearance in gastric cancer animal study

For personal use only

- Five out of seven (71%) animals treated with the cells survived and showed no sign of tumours after 60-days
- Cytokine-armoured cells in a sub-group eliminated tumours in all treated animals




### Mouse model of advanced gastric cancer





**Figure 1: Survival.** Kaplan-Meier survival curve of the intraperitoneal gastric cancer model for animals treated with CAR-iNKT cells or PBS. Log-rank with Holm-Bonferroni correction; * $p<0.05$, ** $p<0.005$.






**Figure 2:** Bioluminescent imaging of tumour progression. Animals were imaged weekly using IVIS bioluminescent imaging to measure tumour burden of luciferase-expressing NUGC4-CLDN18.2 gastric cancer cells

# ALA-105 path to IND filing



File IND with the FDA

Complete IND-enabling studies

Manufacture GMP CLDN18.2 CAR lentivirus

**Process Development to manufacture ALA-105**

**INTERACT and preIND meetings with FDA**

**KOL engagement and clinical trial Protocol**

**Test CLDN18.2 CAR-iNKT cells in mouse models with IL-12 armouring**

**Confirm benefit of IL-12-TM in CLDN18.2 CAR-iNKT cells**

**Test CLDN18.2 CAR in iNKT cells in vitro**

**Develop in vitro and in vivo models to test CLDN18.2 CAR-engineered cells**

**License a CLDN18.2-specific monoclonal antibody (mAb)**

**Expected H1 CY227**

**ALA-105** (CLDN18.2 CAR-iNKT)

For personal use only

# Summary: One platform - three value-creation pathways

For personal use only

Core platform: healthy-donor iNKT cells + modular CAR backbone + scalable manufacturing

Blood cancer validation -> autoimmunity expansion -> solid-tumour expansion

## CD19+ blood cancers (ALA-101)

- CD19 is a validated target for blood cancers
- Proves safety, dosing & persistence of CAR-iNKT cells
- Creates regulatory & CMC precedent
- Generates B cell depletion data




## CD19+ autoimmune disease (ALA-101)

- Leverages B cell depletion data from ALA-101 phase 1 trial
- Indications prioritized based on emerging CAR-T clinical data

## CLDN18.2+ solid tumours (ALA-105)

- Gastric first; pancreatic later
- Tests iNKT solid-tumour biology
- Leverages armouring technology
- Supports expansion to future solid tumour CAR targets

# Arovella's expanding pipeline

| PRODUCT | INDICATION | PRECLINICAL | IND-ENABLING | PHASE 1 |
|---|---|---|---|---|
| **ALA-101** (CD19 CAR-iNKT)  | CD19-positive cancers and autoimmune disease | CD19-positive Lymphoma; Autoimmune disease | | |
| **ALA-105** (CLDN18.2 CAR-iNKT)  | CLDN18.2-positive solid tumours | Gastric & Pancreatic Cancers | | |
| **Product 3**  | New solid tumour target | TBC | | |

For personal use only

## Upcoming Milestones

### ALA-101
- Preliminary safety and efficacy data from phase 1 trial
- Regulatory filings to expand to autoimmune disease

### ALA-105
- Engagement with FDA
- Manufacturing scale-up to GMP

### Pipeline expansion
- Identify priority solid tumour target for pipeline expansion

# Strong Leadership Team

## SENIOR MANAGEMENT TEAM



Dr Nicole van der Weerden
**CHIEF EXECUTIVE OFFICER**

Drug development, regulatory, governance



Dr Robson Dossa
**VP MANUFACTURING & QUALITY**

Cell therapy manufacturing and CMC



Dr Michelle Ferguson
**SENIOR DIRECTOR RESEARCH & DEVELOPMENT**

Translational research and platform expansion



Jacqueline Cumming
**SENIOR DIRECTOR CLINICAL DEVELOPMENT**

International multi-centre trial delivery

**KEY STRENGTHS**

## BOARD OF DIRECTORS



David Williams
**CHAIR**

Capital markets and governance



Dr Michael Thurn
**DIRECTOR**

Clinical and regulatory strategy



Mark Diamond
**DIRECTOR**

Commercialisation and partnering

For personal use only

# Financial overview

## Financial Snapshot

| ASX CODE | ALA |
|---|---|
| Market capitalisation[1] | $61.65 million |
| Shares on issue | 1,208.8 million |
| 52-week low / high | $0.047 / $0.100 |
| Cash Balance (30 September 2026) | **$15.6 million**[2] |

## Major Shareholders

| Shareholder | Ownership (%) [3] |
|---|---|
| BIOTECH CAPITAL MANAGEMENT[4] | 129,606,597 (10.72%) |
| RICHARD JOHN MANN[5] | 68,487,674 (5.67%) |
| NETWEALTH INVESTMENTS LIMITED WRAP SERVICES A/C | 33,595,541 (2.78%) |
| NETWEALTH INVESTMENTS LIMITED SUPER SERVICES A/C | 30,619,851 (2.70%) |
| AJAVA HOLDINGS PTY LTD | 30,000,000 (2.48%) |

1. *As of 29 October 2026*
2. *Includes $4 million R&D tax refund received on 22 October 2026*
3. *As of 30 June 2026*
4. *Formerly Merchant Funds Management*
5. *Holding includes associated entities and parties*




For personal use only



For personal use only

# Chair Address

Mr David Williams

- **Technology Blood**
- Trial in Blood
- Hospital and Manufacturing Infrastructure
- **Technology in Tumours**
- Animal Data in Tumours
- Path to FDA
- Manufacturing Arrangements
- New Hires:
  - Director – Regulatory
  - Director – Preclinical
  - Development Scientist
- Expanded Accommodation
- Immune Evasion Technology
- Tokyo Bright Path
- Platform Technology



For personal use only

# Interview with Jacqueline Cumming:

# Clinical Development

For personal use only

# Interview with Michelle Ferguson:

# Research & Development



ASX:**ALA**

For personal use only

arovella THERAPEUTICS

# Q&A

## Dr Nicole Van Der Weerden

CEO



For personal use only



# Other Business

ASX:**ALA**

For personal use only

arovella THERAPEUTICS

# Thank You

Email: investor@arovella.com
Mobile: +61 403 468 187

David Williams: dwilliams@kidder.com.au
Mobile: +61 414 383 593

Nicole van der Weerden: nvdweerden@arovella.com
Mobile: +61 407 039 983



# Appendix - references


1. https://www.businesswire.com/news/home/20250210311887/en/CAR-T-Cell-Therapy-Market-Industry-Trends-and-Global-Forecasts-to-2035-CD19-and-BCMA-Have-Emerged-as-the-Most-Popular-Target-Antigens---ResearchAndMarkets.com
2. Zinzi et al., 2023 Pharmacological Research - 10.1016/j.phrs.2023.106742
3. https://www.stocktitan.net/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-2y78tisir6kt.html
4. https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html
5. https://bullfincher.io/companies/bristol-myers-squibb-company/revenue-by-segment
6. https://ashpublications.org/blood/article/124/18/2824/33380/Invariant-NKT-cells-with-chimeric-antigen-receptor
7. https://www.nature.com/articles/s43018-024-00830-0
8. https://ashpublications.org/blood/article/147/2/180/547084/Off-the-shelf-dual-CAR-iNKT-cell-immunotherapy


For personal use only